OncoMatch/Clinical Trials/NCT06530550
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Is NCT06530550 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies PI3K inhibitor for lymphoma, t-cell.
Treatment: PI3K inhibitor — Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T/NK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, prospective clinical trial aimed at evaluating the feasibility, efficacy, and safety of PI3K inhibitors in the treatment of relapsed/refractory indolent T/NK-cell lymphomas. Patients will be treated with Linperlisib or Duvelisib, with an expected overall response rate of 60% for PI3K inhibitor treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received: PI3K inhibitor
Subjects who have previously used any PI3K inhibitors
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 90 days before the first dose of study treatment
Received autologous hematopoietic stem cell transplantation within 90 days before the first dose of study treatment
Cannot have received: allogeneic bone marrow or hematopoietic stem cell transplantation
history of allogeneic bone marrow or hematopoietic stem cell transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06530550 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PI3K inhibitor, autologous hematopoietic stem cell transplantation, allogeneic bone marrow or hematopoietic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages